StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

Galectin Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Galectin Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$15.89M. For fiscal 2025 it was -$23.88M. The highest annual figure on record is -$3.10M in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.88M–
FY2024Dec 31, 2024-$41.77M–
FY2023Dec 31, 2023-$32.97M–
FY2022Dec 31, 2022-$31.06M–
FY2021Dec 31, 2021-$24.31M–
FY2020Dec 31, 2020-$20.60M–
FY2019Dec 31, 2019-$10.85M–
FY2018Dec 31, 2018-$10.18M–
FY2017Dec 31, 2017-$15.89M–
FY2016Dec 31, 2016-$16.41M–
FY2015Dec 31, 2015-$16.98M–
FY2014Dec 31, 2014-$12.43M–
FY2013Dec 31, 2013-$7.48M–
FY2012Dec 31, 2012-$7.50M–
FY2011Dec 31, 2011-$5.68M–
FY2010Dec 31, 2010-$3.10M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.44M–
Q1 FY2026Mar 31, 2026-$3.87M–
Q4 FY2025Dec 31, 2025-$6.04M–
Q3 FY2025Sep 30, 2025-$3.54M–
Q2 FY2025Jun 30, 2025-$6.60M–
Q1 FY2025Mar 31, 2025-$7.69M–
Q4 FY2024Dec 31, 2024-$12.79M–
Q3 FY2024Sep 30, 2024-$8.54M–
Q2 FY2024Jun 30, 2024-$8.33M–
Q1 FY2024Mar 31, 2024-$12.11M–
Q4 FY2023Dec 31, 2023-$4.70M–
Q3 FY2023Sep 30, 2023-$7.64M–
Q2 FY2023Jun 30, 2023-$9.83M–
Q1 FY2023Mar 31, 2023-$10.79M–
Q4 FY2022Dec 31, 2022-$7.24M–
Q3 FY2022Sep 30, 2022-$8.35M–
Q2 FY2022Jun 30, 2022-$7.43M–
Q1 FY2022Mar 31, 2022-$8.04M–
Q4 FY2021Dec 31, 2021-$6.95M–
Q3 FY2021Sep 30, 2021-$5.00M–
Q2 FY2021Jun 30, 2021-$5.98M–
Q1 FY2021Mar 31, 2021-$6.38M–
Q4 FY2020Dec 31, 2020-$5.41M–
Q3 FY2020Sep 30, 2020-$8.21M–
Q2 FY2020Jun 30, 2020-$2.60M–
Q1 FY2020Mar 31, 2020-$4.37M–
Q4 FY2019Dec 31, 2019-$3.76M–
Q3 FY2019Sep 30, 2019-$1.48M–
Q2 FY2019Jun 30, 2019-$2.33M–
Q1 FY2019Mar 31, 2019-$3.28M–
Q4 FY2018Dec 31, 2018-$2.01M–
Q3 FY2018Sep 30, 2018-$1.58M–
Q2 FY2018Jun 30, 2018-$3.08M–
Q1 FY2018Mar 31, 2018-$3.52M–
Q4 FY2017Dec 31, 2017-$3.90M–
Q3 FY2017Sep 30, 2017-$3.12M–
Q2 FY2017Jun 30, 2017-$5.00M–
Q1 FY2017Mar 31, 2017-$3.86M–
Q4 FY2016Dec 31, 2016-$4.87M–
Q3 FY2016Sep 30, 2016-$3.44M–

More Galectin Therapeutics figures

See a number that looks wrong?